Visikol

Visikol is a CRO focused on advanced drug discovery that is leading the field of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

Visikol headquartered in United States, North America, operates in the Developer Tools, Information Technology, Biotechnology, Analytics, Neuroscience sector. The company focuses on Developer Tools and has secured $854.8M in funding across 180 round(s). With a team of 11-50 employees, Visikol is actively contributing to advancements in Developer Tools. Their latest funding round, Seed Round - Visikol, raised $500.0K. Discover more about their projects, partnerships, and impact on our platform.